BioCentury
ARTICLE | Company News

Novo gains European approval for diabetes drug Ozempic

February 9, 2018 8:47 PM UTC

Novo Nordisk A/S (CSE:NOVOB; NYSE:NVO) said the European Commission approved subcutaneous Ozempic semaglutide (NN9535) to treat Type II diabetes in adults. Novo plans to launch the therapy next half.

The product is indicated for use as a monotherapy when metformin is considered inappropriate due to intolerance or is contraindicated. It is also indicated for use in combination with other diabetes treatments...

BCIQ Company Profiles

Novo Nordisk A/S